Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.

Ferrannini G, Gerstein H, Colhoun HM, Dagenais GR, Diaz R, Dyal L, Lakshmanan M, Mellbin L, Probstfield J, Riddle MC, Shaw JE, Avezum A and 13 more

Show all authors

Basile JN, Cushman WC, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Pais P, Pīrāgs V, Pogosova N, Raubenheimer PJ, Sheu WH, Rydén L

European heart journal1 Jul 2021Cited by 19 (Europe PMC)

PMID33197271DOI10.1093/eurheartj/ehaa777PepBankPUB-33197271

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In REWIND patients taking metformin at baseline, dulaglutide had a primary cardiovascular outcome hazard ratio of 0.92 versus placebo.
In plain wordsIn patients taking metformin at baseline, the cardiovascular outcome hazard ratio for dulaglutide versus placebo was 0.92.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedPrimary CV composite with baseline metformin
Study
n = 8,037
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1.5 mg weekly · subcutaneousAs given in this study (human).
Measurements
Hazard ratio
0.92 ratio
baseline metformin
CI lower
0.81 ratio
baseline metformin
CI upper
1.05 ratio
baseline metformin
Source sentences
Summary
There was no significant difference in the effect of dulaglutide on the primary outcome in patients with vs. without metformin at baseline [HR 0.92 (CI 0.81-1.05) vs. 0.78 (CI 0.61-0.99); interaction P = 0.18].
3 context sentences(design, population, supporting numbers)
Summary · context
Patients in REWIND (n = 9901; women: 46.3%; mean age: 66.2 years) had type 2 diabetes and either a previous CV event (31%) or high CV risk (69%).
Summary · context
They were randomized (1:1) to sc. dulaglutide (1.5 mg/weekly) or placebo in addition to standard of care.
Summary · context
The primary outcome was the first of a composite of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular or unknown causes.
Report a problemFND-3319727101
02HumanRandomized controlled trialEfficacy outcome
In REWIND patients without baseline metformin, dulaglutide had a primary cardiovascular outcome hazard ratio of 0.78 versus placebo.
In plain wordsIn patients without baseline metformin, dulaglutide reduced cardiovascular event risk compared with placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePrimary CV composite without baseline metformin
Study
n = 1,864
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
1.5 mg weekly · subcutaneousAs given in this study (human).
Measurements
Hazard ratio
0.78 ratio
without baseline metformin
CI lower
0.61 ratio
without baseline metformin
CI upper
0.99 ratio
without baseline metformin
Source sentences
Summary
There was no significant difference in the effect of dulaglutide on the primary outcome in patients with vs. without metformin at baseline [HR 0.92 (CI 0.81-1.05) vs. 0.78 (CI 0.61-0.99); interaction P = 0.18].
3 context sentences(design, population, supporting numbers)
Summary · context
Patients in REWIND (n = 9901; women: 46.3%; mean age: 66.2 years) had type 2 diabetes and either a previous CV event (31%) or high CV risk (69%).
Summary · context
They were randomized (1:1) to sc. dulaglutide (1.5 mg/weekly) or placebo in addition to standard of care.
Summary · context
The primary outcome was the first of a composite of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular or unknown causes.
Report a problemFND-3319727102

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In REWIND patients, dulaglutide effects on key secondary outcomes were similar with and without baseline metformin.
In plain wordsDulaglutide's effects on other main outcomes were similar in patients with and without baseline metformin.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeKey secondary outcome subgroup patterns
Study
n = 9,901
Comparator
Without baseline metformin
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Findings for key secondary outcomes were similar in patients with and without baseline metformin.
4 context sentences(design, population, supporting numbers)
Summary · context
Key secondary outcomes included a microvascular composite endpoint, all-cause death, and heart failure.
Summary · context
Patients in REWIND (n = 9901; women: 46.3%; mean age: 66.2 years) had type 2 diabetes and either a previous CV event (31%) or high CV risk (69%).
Summary · context
They were randomized (1:1) to sc. dulaglutide (1.5 mg/weekly) or placebo in addition to standard of care.
Summary · context
The primary outcome was the first of a composite of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular or unknown causes.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3319727104
04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In REWIND patients, baseline metformin did not significantly modify dulaglutide's primary cardiovascular outcome effect.
In plain wordsDulaglutide's cardiovascular effect did not differ significantly between patients with and without baseline metformin.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeMetformin interaction with CV effect
Study
n = 9,901
Comparator
Without baseline metformin
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Interaction P
0.18 P
with versus without baseline metformin
Source sentences
Summary
There was no significant difference in the effect of dulaglutide on the primary outcome in patients with vs. without metformin at baseline [HR 0.92 (CI 0.81-1.05) vs. 0.78 (CI 0.61-0.99); interaction P = 0.18].
3 context sentences(design, population, supporting numbers)
Summary · context
Patients in REWIND (n = 9901; women: 46.3%; mean age: 66.2 years) had type 2 diabetes and either a previous CV event (31%) or high CV risk (69%).
Summary · context
They were randomized (1:1) to sc. dulaglutide (1.5 mg/weekly) or placebo in addition to standard of care.
Summary · context
The primary outcome was the first of a composite of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular or unknown causes.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3319727103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.